ALLOUCHERY, M.; PERAULT-POCHAT, M. C.; SALVO, Francesco

doi:10.1111/fcp.13014

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

ALLOUCHERY, M.

PERAULT-POCHAT, M. C.

SALVO, Francesco
Bordeaux population health [BPH]

Langue

Article de revue

Ce document a été publié dans

Fundamental & Clinical Pharmacology. 2024-06-01, vol. 38, n° S1, p. 43-44

Résumé en anglais

Despite being a standard of care in B-cell malignancies, a benefit–risk assessment in real-life set- tings of ibrutinib, the first-in-class Bruton tyrosine kinase (BTK) inhibitor, was still needed. This work aimed to provide real-life data on patterns of use and safety of ibrutinib through two data sources, VigiBase® and SNDS. Firstly, co-administration of ibrutinib and anticoagulants was associated with a 2.5-fold increased risk of clinically relevant bleeding, without any difference between vitamin K antagonists and direct oral anticoagulants. Secondly, 1-year incidence of fungal invasive infections was 1.3% in ibrutinib- treated patients, with the following predictive factors: stem cell transplantation, neutropenia, corticosteroids, and chronic respiratory diseases, previous treatment and combination with anti-CD20 agents. Lastly, rele- vant safety signals emerged from VigiBase®, mainly cardiovascular and ocular reactions. Taken together, these findings contributed to providing essential information about monitoring and management of ibrutinib-treated patients and crucial insights for real- world surveillance of next-generation BTK inhibitors< Réduire

Mots clés en anglais

Ibrutinib

Pharmacoepidemiology

Pharma-Covigilance

Targeted Therapy

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Patterns of use and safety of ibrutinib inreal-life practice in onco-hematology

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche